Yervoy Approval Has Shifted Development Landscape For Melanoma
Executive Summary
With Bristol-Myers Squibb Co.’s ipilimumab cleared and Roche/Daiichi Sankyo’s BRAF inhibitor vemurafenib (RG7204) on track for a filing and perhaps approval this year, companies developing other melanoma drugs face a more complicated, competitive path to market.
You may also be interested in...
Cancer Immunotherapies Have FDA, Industry Looking For New Endpoints
Modifying existing tumor response criteria or developing novel intermediate endpoints could address shortfalls in immuno-oncology efficacy assessments with traditional endpoints such as overall response rate and progression-free survival.
Amgen’s Imlygic Approval A Milestone For Oncolytic Cancer Vaccines
Company prices Imlygic (T-VEC) cancer vaccine at the average cost of $65,000, aims to launch within a week.
Merck’s Keytruda Opens Door, But Combination Trials Could Unlock Efficacy
FDA’s approval of Merck’s anti-PD-1 drug pembrolizumab in melanoma marks a major milestone for oncology and industry’s immune checkpoint efforts. But with an overall response rate in labeling of 24%, there’s still room for improvement with combinations and use in earlier lines of therapy.